Literature DB >> 3928801

Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts.

S Manabe, S Sassa, A Kappas.   

Abstract

Succinylacetone (SA) (4,6-dioxoheptanoic acid) is an abnormal metabolite produced in patients with hereditary tyrosinemia as a consequence of an inherited deficiency of fumaryl acetoacetate hydrolase activity. Patients with this disease are associated with a number of abnormalities, including aminoaciduria, proteinuria, liver failure, commonly hepatoma, and decreased GSH concentration in the liver. In the course of our studies of tyrosinemia, we found that the urine of patients with this disorder contains material(s) that absorbs light at 315 nm. We investigated the nature of the 315 nm material in detail. SA was found to react with amino acids and protein nonenzymatically, to form stable adducts at physiological temperature and pH. All SA adducts with amino acids and/or proteins exhibited an absorption peak at 315 nm. Although all amino acids reacted with SA, the most reactive amino acid was lysine (Lys), followed, in order, by glycine, methionine, phenylalanine, serine, alanine, and glutamine. SA-adducts were unstable at pH below 6, while they were made considerably more stable after reduction with NaBH4, suggesting that SA forms an adduct via Schiff base formation. High-performance liquid chromatography (HPLC) analysis of urines from patients with tyrosinemia revealed the existence of SA-glycine, SA-methionine, SA-tyrosine, and SA-phenylalanine. After digestion of urines with proteinase K, three more HPLC peaks appeared, which all corresponded to SA-Lys adducts. TLC analysis of SA-Lys showed that SA-Lys could form as many as seven different adducts. No SA-adduct peaks were observed in HPLC in urines from normal subjects, patients with other forms of aminoaciduria, or patients with the nephrotic syndrome. In addition to amino acids and proteins, SA reacted with reduced glutathione (GSH) and formed a stable adduct. These findings suggest that SA adduct formation with amino acids, GSH, and proteins is a significant process occurring in tyrosinemia, and may account for certain of the pathologic findings in this hereditary disorder.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928801      PMCID: PMC2187807          DOI: 10.1084/jem.162.3.1060

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  15 in total

1.  STUDIES ON TYROSINOSIS: 1, EFFECT OF LOW-TYROSINE AND LOW-PHENYLALANINE DIET.

Authors:  S HALVORSEN; L R GJESSING
Journal:  Br Med J       Date:  1964-11-07

2.  Inhibition of delta-aminolevulinic acid dehydrase by 4,6-dioxoheptanoic acid.

Authors:  D P Tschudy; R A Hess; B C Frykholm
Journal:  J Biol Chem       Date:  1981-10-10       Impact factor: 5.157

3.  Dietary treatment in tyrosinemia (tyrosinosis). With a note on the possible recognition of the carrier state.

Authors:  J Gentz; B Lindblad; S Lindstedt; L Levy; W Shasteen; R Zetterstrom
Journal:  Am J Dis Child       Date:  1967-01

4.  On the renal tubular damage in hereditary tyrosinemia and on the formation of succinylacetoacetate and succinylacetone.

Authors:  S P Fällström; B Lindblad; G Steen
Journal:  Acta Paediatr Scand       Date:  1981

5.  Detection of succinylacetone and the use of its measurement in mass screening for hereditary tyrosinemia.

Authors:  A Grenier; A Lescault; C Laberge; R Gagné; O Mamer
Journal:  Clin Chim Acta       Date:  1982-08-04       Impact factor: 3.786

6.  The principal site of nonenzymatic glycosylation of human serum albumin in vivo.

Authors:  R L Garlick; J S Mazer
Journal:  J Biol Chem       Date:  1983-05-25       Impact factor: 5.157

7.  Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone.

Authors:  S Sassa; A Kappas
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

8.  Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose.

Authors:  S Pongor; P C Ulrich; F A Bencsath; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

9.  Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts.

Authors:  S Manabe; R Bucala; A Cerami
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

10.  On the enzymic defects in hereditary tyrosinemia.

Authors:  B Lindblad; S Lindstedt; G Steen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

View more
  5 in total

1.  Tyrosinaemia type I with normal levels of plasma tyrosine.

Authors:  I T de Almeida; P P Leandro; M F Silva; C Silveira; A da Silva; J S de Sousa; M Duran
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

2.  Point mutation instability (PIN) mutator phenotype as model for true back mutations seen in hereditary tyrosinemia type 1 - a hypothesis.

Authors:  Etresia van Dyk; Pieter J Pretorius
Journal:  J Inherit Metab Dis       Date:  2011-10-15       Impact factor: 4.982

Review 3.  Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism.

Authors:  Ayelet Erez; Oleg A Shchelochkov; Sharon E Plon; Fernando Scaglia; Brendan Lee
Journal:  Am J Hum Genet       Date:  2011-04-08       Impact factor: 11.025

4.  Deficient DNA-ligase activity in the metabolic disease tyrosinemia type I.

Authors:  M J Prieto-Alamo; F Laval
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

5.  Murine fumarylacetoacetate hydrolase (Fah) gene is disrupted by a neonatally lethal albino deletion that defines the hepatocyte-specific developmental regulation 1 (hsdr-1) locus.

Authors:  M L Klebig; L B Russell; E M Rinchik
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.